Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology

The Biology of Bleeding: Genetics & Severity

At a Glance

Hemophilia severity depends on the percentage of active clotting factors (VIII or IX) in your blood. Because it is an X-linked genetic condition, it primarily affects males, but female carriers can also have low factor levels and experience serious bleeding symptoms.

To understand hemophilia, it helps to look at the body’s internal “construction crew” for stopping leaks. When you get a cut or an internal injury, your body triggers a complex chain reaction called the coagulation cascade. This process uses various proteins, called clotting factors, to build a stable plug (a clot) to stop the bleeding [1][2].

The Role of Factor VIII and Factor IX

In the coagulation cascade, factors work together like a series of falling dominoes. Factor VIII (missing in Hemophilia A) and Factor IX (missing in Hemophilia B) are critical “middlemen” in this process [3].

  • The Partnership: Normally, Factor IX acts as an enzyme that activates other proteins, while Factor VIII acts as a “cofactor” or helper that speeds up this process by thousands of times [3][4].
  • The Disruption: If either one is missing, the “dominoes” stop falling. The body can still form a weak, temporary plug, but it cannot create the strong, lasting fibrin clot needed to truly stop the bleed [4][5].

Understanding Severity Levels

Doctors classify hemophilia based on the percentage of clotting factor active in your blood compared to a “normal” person (who has 50% to 150%). This percentage helps predict how often and how severely a person might bleed [5].

Severity Factor Level What it means in practice
Severe <1% Bleeding can occur “spontaneously” without a clear injury. Frequent bleeds into joints or muscles are common [6][7].
Moderate 1% - 5% Bleeding usually happens after a minor injury (like a fall or a sports bump). Spontaneous bleeding is rare but possible [5].
Mild 5% - 40% Bleeding usually only occurs after a major injury, surgery, or dental work. It may go undiagnosed for years [8].

Genetics: The X-Linked Pattern

Hemophilia is an X-linked recessive disorder, which refers to the way the genes are passed down on the X and Y chromosomes [9].

  • Males (XY): Have only one X chromosome. If the gene on that X chromosome is faulty, they will have hemophilia.
  • Females (XX): Have two X chromosomes. Typically, if one X has the faulty gene, the other “healthy” X chromosome provides enough factor to prevent severe symptoms. These women are often called carriers [10][11].

“Carriers” Can Bleed Too

For a long time, it was believed that only males could have symptoms of hemophilia. We now know this is incorrect. Many women who carry the gene have factor levels low enough to cause real medical issues [12][13].

  • Lyonization: In every cell of a female’s body, one of the two X chromosomes is randomly “turned off.” If, by chance, the “healthy” X is turned off in most of the liver cells (where clotting factors are made), that woman will have low factor levels [14][15].
  • Symptoms: These women may experience heavy menstrual bleeding (menorrhagia), frequent nosebleeds, or excessive bleeding after dental work or childbirth [12][16].
  • New Terminology: Modern guidelines now distinguish between symptomatic carriers (those with symptoms but factor levels above 40%) and women who actually meet the clinical definition of hemophilia in females (factor levels below 40%) [17][14][18]. Regardless of the label, these symptoms require medical management and recognition [19].

Common questions in this guide

What determines if hemophilia is mild, moderate, or severe?
Severity is based on the percentage of active clotting factor in your blood compared to a person without the condition. Severe hemophilia has less than 1% factor activity, moderate has 1% to 5%, and mild has 5% to 40%.
Can female carriers have symptoms of hemophilia?
Yes, females who carry the hemophilia gene can experience real bleeding symptoms. Depending on how their X chromosomes activate, some women have low enough clotting factor levels to cause heavy periods, frequent nosebleeds, or excessive bleeding after procedures.
What is the difference between Factor VIII and Factor IX?
Both are proteins your body needs to form a stable blood clot. A deficiency in Factor VIII causes Hemophilia A, while a deficiency in Factor IX causes Hemophilia B. If either is missing, the body cannot create the strong clot needed to stop a bleed.
Should female relatives of someone with hemophilia get tested?
Yes, modern guidelines recommend that female relatives, such as mothers, sisters, and daughters, have their clotting factor levels checked. This helps identify if they have low levels that could cause excessive bleeding during surgery, dental work, or childbirth.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific factor activity level (in percentage) that was found during testing?
  2. 2.Based on my/my child's genetic mutation, is there a predictable bleeding pattern or risk for developing inhibitors?
  3. 3.Should the female relatives in our family (mothers, sisters, daughters) have their factor levels tested, even if they don't have obvious symptoms?
  4. 4.If a female relative has low factor levels but is above 40%, what is the proper term for her diagnosis (e.g., 'symptomatic carrier')?
  5. 5.How do you typically manage bleeding risks for mild or moderate cases during minor procedures like dental work?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Practices and challenges for hemophilia management under resource constraints in Thailand.

    Moonla C, Sosothikul D, Pongtanakul B, et al.

    Orphanet journal of rare diseases 2023; (18(1)):110 doi:10.1186/s13023-023-02718-1.

    PMID: 37161533
  2. 2

    [Treatment of haemophilia: From replacement to gene therapy].

    Páramo JA

    Medicina clinica 2021; (157(12)):583-587 doi:10.1016/j.medcli.2021.04.031.

    PMID: 34509300
  3. 3

    Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

    Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B

    Thrombosis and haemostasis 2020; (120(10)):1357-1370 doi:10.1055/s-0040-1714279.

    PMID: 32717759
  4. 4

    Hemophilia A: Emicizumab monitoring and impact on coagulation testing.

    Nardi MA

    Advances in clinical chemistry 2023; (113()):273-315 doi:10.1016/bs.acc.2022.12.001.

    PMID: 36858648
  5. 5

    Clinical pattern of hemophilia and causes of variability.

    Mingot-Castellano ME

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2019; (30(1S Suppl 1)):S4-S6 doi:10.1097/MBC.0000000000000821.

    PMID: 31517708
  6. 6

    Prevalence of Hemophilia and Clinicodemographic Characteristics of Hemophilic Patients Aged ≤ 18 Years in Thi-Qar, Iraq.

    Abood GM, Dehiol RK, Mones HM

    Global pediatric health 2024; (11()):2333794X241280119 doi:10.1177/2333794X241280119.

    PMID: 39281354
  7. 7

    Gene therapy for hemophilia: looking beyond factor expression.

    Yamaguti-Hayakawa GG, Ozelo MC

    Experimental biology and medicine (Maywood, N.J.) 2022; (247(24)):2223-2232 doi:10.1177/15353702221147565.

    PMID: 36691324
  8. 8

    Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

    Johnston K, Stoffman JM, Mickle AT, et al.

    Patient preference and adherence 2021; (15()):1407-1417 doi:10.2147/PPA.S316276.

    PMID: 34194224
  9. 9

    Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B.

    Lu L, Wang L, Shen W, et al.

    Molecular genetics & genomic medicine 2023; (11(5)):e2147 doi:10.1002/mgg3.2147.

    PMID: 36795372
  10. 10

    Molecular characterization of hemophilia B patients in Colombia.

    Parrado Jara YA, Yunis Hazbun LK, Linares A, Yunis Londoño JJ

    Molecular genetics & genomic medicine 2020; (8(5)):e1210 doi:10.1002/mgg3.1210.

    PMID: 32155688
  11. 11

    The Clinical Genetics of Hemophilia B (Factor IX Deficiency).

    Miller CH

    The application of clinical genetics 2021; (14()):445-454 doi:10.2147/TACG.S288256.

    PMID: 34848993
  12. 12

    Hemophilia and Other Congenital Coagulopathies in Women.

    Green D

    Journal of hematology 2024; (13(4)):137-141 doi:10.14740/jh1298.

    PMID: 39247065
  13. 13

    Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues.

    Weyand AC, Sidonio RF, Sholzberg M

    Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28 Suppl 4()):18-25 doi:10.1111/hae.14535.

    PMID: 35521724
  14. 14

    Genetic causes of haemophilia in women and girls.

    Miller CH, Bean CJ

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(2)):e164-e179 doi:10.1111/hae.14186.

    PMID: 33314404
  15. 15

    Six molecular patterns leading to hemophilia A phenotype in 18 females from Poland.

    Janczar S, Babol-Pokora K, Jatczak-Pawlik I, et al.

    Thrombosis research 2020; (193()):9-14 doi:10.1016/j.thromres.2020.05.041.

    PMID: 32497951
  16. 16

    Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review.

    Livanou ME, Matsas A, Valsami S, et al.

    Life (Basel, Switzerland) 2023; (13(6)) doi:10.3390/life13061321.

    PMID: 37374104
  17. 17

    Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding.

    Hermans C, Johnsen JM, Curry N

    Haemophilia : the official journal of the World Federation of Hemophilia 2024; (30 Suppl 3()):45-51 doi:10.1111/hae.14983.

    PMID: 38532560
  18. 18

    Hemophilia A in Females: Considerations for Clinical Management.

    Bryant P, Boukouvala A, McDaniel J, Nance D

    Acta haematologica 2020; (143(3)):289-294 doi:10.1159/000503889.

    PMID: 31825922
  19. 19

    Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A.

    Srivaths L, Larson J, Saroukhani S, et al.

    Journal of thrombosis and haemostasis : JTH 2025; (23(2)):504-512 doi:10.1016/j.jtha.2024.10.030.

    PMID: 39536816

This page provides educational information about hemophilia genetics and severity. It is for informational purposes only and does not replace professional medical advice or genetic counseling. Always consult your hematologist regarding your specific condition.

Get notified when new evidence is published on Hemophilia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.